| (Values in U.S. Thousands) | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 | Sep, 2017 |
| Sales | 15,680 | 0 | 0 | 0 | -32,560 |
| Sales Growth | unch | unch | unch | +100.00% | -49.84% |
| Net Income | -87,620 | -70,370 | -44,900 | -19,530 | 40,620 |
| Net Income Growth | -24.51% | -56.73% | -129.90% | -148.08% | +0.59% |
Forty Seven Inc (FTSV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP' receptor on macrophages. Forty Seven, Inc. is based in CA, United States.
Fiscal Year End Date: 12/31